GlassScriptPhysician profile
Thomas Benjamin Karasic
NPI 1760742050
$16,532.42
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,613 · 2020: $5,900 · 2021: $2,398 · 2022: $6,545 · 2024: $77.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $77.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $77.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $4,200.00 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $3,200.00 | 2022 | |
| Pfizer INC. | $3,000.00 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $2,500.55 | 2021-2022 | |
| Taiho Oncology, INC. | $1,742.00 | 2022 | |
| Incyte Corporation | $1,700.00 | 2020 | |
| Eisai INC. | $189.87 | 2019-2024 |
8 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Karasic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.